In 2017, the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA) approved the first tyrosine kinase inhibitor (TKI) midostaurin in combination with chemotherapy for FLT3-mutated AML based on data of a large randomized phase 3 study [5]. This evidence concerns the gene FLT3 and acute myeloid leukemia.